Sun Xingwei, Bai Xuming, Zhang Yu, Xu Liang, Yu Zepeng, Jin Yong, Zhuang Zhixiang
Department of Intervention, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, China.
Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, China.
J Cancer. 2021 Jan 1;12(5):1379-1385. doi: 10.7150/jca.55343. eCollection 2021.
To evaluate the safety and efficacy of ultrasound (US)-guided totally implantable venous access ports (TIVAPs) via the right brachiocephalic vein (BCV) or the left BCV approach. : Patients requiring TIVAP for chemotherapy were included in the study. US-guided TIVAPs via BCV were used for patients from July 2018 to December 2018. General information about the patients (sex, age, and diagnosis), side (right or left), surgical procedures and complications were recorded. A total of 107 TIVAPs in 107 patients (ages 38-73 years) were included, 75 via the right BCV and 32 via the left BCV. All of the patients underwent successful surgery. The BCV was successfully punctured on the first attempt in 99 patients (92.52%). Two attempts were needed in 6 patients (5.61%), and three attempts were necessary in 2 patients (1.87%). The mean operation time was 29 ± 5 min (range: 24 to 38 min). No serious complications occurred during the surgery, except the formation of a local haematoma in 1 case after artery puncture. During the follow-up period of 12 months, the incidence of long-term complications was 3.74% (4/107), including 2 cases of catheter-related infection and 2 cases of fibrin sheath formation. No serious complications such as catheter malposition or rupture were found. US-guided TIVAP via the BCV offers an alternative for adults with good needle guidance and a low rate of perioperative and postoperative complications.
评估经右头臂静脉（BCV）或左头臂静脉途径超声（US）引导下完全植入式静脉通路端口（TIVAP）的安全性和有效性。：纳入需要TIVAP进行化疗的患者。2018年7月至2018年12月期间对患者采用经BCV的US引导下TIVAP。记录患者的一般信息（性别、年龄和诊断）、穿刺侧（右侧或左侧）、手术过程及并发症。共纳入107例患者（年龄38 - 73岁）的107个TIVAP，其中经右BCV途径75个，经左BCV途径32个。所有患者手术均成功。99例患者（92.52%）首次穿刺成功进入BCV。6例患者（5.61%）需要两次穿刺，2例患者（1.87%）需要三次穿刺。平均手术时间为29±5分钟（范围：24至38分钟）。手术期间除1例动脉穿刺后形成局部血肿外，未发生严重并发症。在12个月的随访期内，长期并发症发生率为3.74%（4/107），包括2例导管相关感染和2例纤维蛋白鞘形成。未发现导管位置异常或破裂等严重并发症。经BCV的US引导下TIVAP为成人提供了一种替代方法，具有良好的穿刺引导且围手术期和术后并发症发生率低。
